Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 2:28 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 9,935 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Single-arm Clear all

Conditions: Antibiotic Prophylaxis
Interventions: Nitrofurantoin; Drug
Lead sponsor: Atlantic Health System; Other
Eligibility: 18 Years and older · Female only
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Morristown, New Jersey

Conditions: IgA Nephropathy (IgAN), Immunoglobulin A Nephropathy (IgAN)
Interventions: atrasentan; Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Colorectal Cancer
Interventions: Pembrolizumab, mFOLFOX6; Drug
Lead sponsor: Hoosier Cancer Research Network; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 3
States / cities: Atlanta, Georgia • Indianapolis, Indiana • Columbus, Ohio

Conditions: Middle Ear Disease, Nasal Allergy
Interventions: ragweed, histamine, pseudoephedrine, Oxymetazoline; Biological · Drug
Lead sponsor: Cuneyt M. Alper; Other
Eligibility: 18 Years to 50 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Wilson Disease
Interventions: Bis-Choline Tetrathiomolybdate; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 3
States / cities: Sacramento, California • Ann Arbor, Michigan • Dallas, Texas

Conditions: Light Chain Deposition Disease, Smoldering Multiple Myeloma
Interventions: Clinical Observation, Lenalidomide, Quality-of-Life Assessment; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2027
U.S. locations: 601
States / cities: Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 390 more

Conditions: Urinary Bladder Cancer, Muscle-invasive
Interventions: Pembrolizumab, Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND]), Enfortumab Vedotin; Drug · Procedure
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 595 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 39
States / cities: Mobile, Alabama • Little Rock, Arkansas • Fullerton, California + 31 more

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: Nelfinavir (Viracept®) 1250 mg, Chemoradiation; Drug · Other
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Tumors
Interventions: Fosbretabulin, Carboplatin, Paclitaxel, Bevacizumab; Drug
Lead sponsor: Mateon Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 15
States / cities: Campbell, California • Fountain Valley, California • Los Angeles, California + 12 more

Conditions: Solid Tumor
Interventions: Bevacizumab, Cyclophosphamide, Valproic Acid, Temsirolimus; Drug
Lead sponsor: Miller Children's & Women's Hospital Long Beach; Other
Eligibility: 12 Months to 31 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2029
U.S. locations: 2
States / cities: Long Beach, California • Orange, California

Conditions: Hemophilia A
Interventions: Recomb. Factor VIII (Kogenate FS Liposome, BAY79-4980), Recombinant Factor VIII (Kogenate FS, BAY14-2222); Biological
Lead sponsor: Bayer; Industry
Eligibility: 12 Years to 60 Years · Male only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 2
States / cities: Davis, California • Orange, California

Conditions: Upper Extremity Weakness, Stroke
Interventions: Sequential Compression Device; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 100 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Saint Johns, Florida

Conditions: Depressive Symptoms, Anxiety, Stress, Impairment
Interventions: e-Health Treatment; Behavioral
Lead sponsor: Stony Brook University; Other
Eligibility: 18 Years and older
Enrollment: 145 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Influenza, Vaccination, Health Promotion, Health Behavior, Risk Reduction
Interventions: Risk reduction, Medical records-based recommendation, Algorithm-based recommendation; Behavioral
Lead sponsor: Geisinger Clinic; Other
Eligibility: 17 Years and older
Enrollment: 117,649 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Danville, Pennsylvania

Conditions: Gastroesophageal Reflux Disorder
Interventions: Symptom questionnaire; Other
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2017
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Follicular Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma
Interventions: ofatumumab; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Environmental Exposure
Interventions: Urinary EDC metabolite testing, Educational curriculum; Diagnostic Test · Behavioral
Lead sponsor: Million Marker Wellness, Inc.; Industry
Eligibility: 18 Years to 44 Years
Enrollment: 1,074 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Reno, Nevada

Conditions: Obesity
Interventions: Exercise program, Nutrition, WLS; Behavioral · Dietary Supplement · Procedure
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 55 Years to 75 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: MTAP-deleted Solid Tumors
Interventions: S095035, TNG462; Drug
Lead sponsor: Servier Bio-Innovation LLC; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 5
States / cities: Lake Mary, Florida • Indianapolis, Indiana • Maumee, Ohio + 2 more

Conditions: Healthy Volunteers
Interventions: TAK-881, SC Investigational Needle Sets; Biological · Device
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Pediatric Cancer, Malnutrition, Child, Caregiver Burden
Interventions: Medically Tailored Meals, Caregiver Coaching; Other · Behavioral
Lead sponsor: Drexel University; Other
Eligibility: 5 Years to 21 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Metastatic Melanoma, Skin Cancer
Interventions: Fludarabine, Cyclophosphamide, Aldesleukin, MART-1 Reactive CD8+ PBL; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Lung Cancer
Interventions: erlotinib; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Lymphoid Leukemia, Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia
Interventions: CPX-351; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Tampa, Florida

Search by objective public record fields.

Use of Prophylactic Antibiotics Prior to OnabotulinumtoxinA

Mechanistic Evaluation of Atrasentan in Patients With IgA Nephropathy (IgAN)

Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer

TransMEM Gas Exchange -- Project 1, Aim 2

Copper Concentration & Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840

Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

Phase II Trial of Nelfinavir With Concurrent Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck

A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer

Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence

Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980

A Study to Evaluate Lower Extremity Sleeve and Pump Device to Treat Hemiparesis

Asynchronous Techniques for the Delivery of Empirically Supported Psychotherapies

Encouraging Flu Vaccination Among High-Risk Patients Identified by ML

Assessing Outcomes After Surgery for Gastroesophageal Reflux Disorder

Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma

A Personalized Biomonitoring and Report-back Intervention to Reduce Exposure to Endocrine Disrupting Chemicals

Surgical vs. Lifestyle in Obese Older Adults

S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP

A Study of TAK-881 With and Without Ramp-Up Dosing in Healthy Adults

From Kitchen to Clinic

Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells

Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or Gefitinib

Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia